Skip to main content
. 2017 Sep 25;8:1103. doi: 10.3389/fimmu.2017.01103

Table 1.

Baseline characteristics of 101 reported chronic and prolonged immunodeficiency-related vaccine-derived poliovirus cases at time of detection, 1962–2016.

Characteristic Number of cases, n/N (%) Prolonged excretor casesa, n/N (%) Chronic excretor casesb, n/N (%)
Total 101 94 7

Gender
Male 63/98 (64) 59/91 (65) 4/7 (57)
Female 35/98 (36) 32/91 (35) 3/7 (43)

Age at onset or first positive specimen
<1 year 46/100 (46) 46/93 (49) 0/7 (0)
1 to <5 years 37/100 (37) 37/93 (40) 0/7 (0)
5 to <10 years 7/100 (7) 6/93 (6) 1/7 (14)
10 to <20 years 5/100 (5) 2/93 (2) 3/7 (43)
20 to <30 years 3/100 (3) 1/93 (1) 2/7 (29)
≥30 years 2/100 (2) 1/93 (1) 1/7 (14)

Paralysis
Yes 71/100 (71) 67/93 (72) 4/7 (57)
No 29/100 (29) 26/93 (28) 3/7 (43)

Country of residence income classificationc
High income 29/101 (29) 22/94 (23) 7/7 (100)
Upper-middle income 47/101 (47) 47/94 (50) 0/7 (0)
Lower-middle income 24/101 (24) 24/94 (26) 0/7 (0)
Low income 1/101 (1) 1/94 (1) 0/7 (0)

WHO region of residence
Eastern Mediterranean Region 43/101 (43) 43/94 (46) 0/7 (0)
African Region 6/101 (6) 6/94(6) 0/7 (0)
Western Pacific Region 10/101 (10) 7/94 (7) 3/7 (43)
European Region 14/101 (14) 10/94 (11) 4/7 (57)
South-East Asian Region 13/101 (13) 13/94 (14) 0/7 (0)
Region of the Americas 15/101 (15) 15/94 (16) 0/7 (0)

Immunodeficiency disorder
SCID and other combined humoral/T-cell deficiencies 27/92 (29) 27/85 (32) 0/7 (0)
SCID 25/92 (27) 25/85 (29) 0/7 (0)
CVID 21/92 (23) 14/85 (16) 7/7 (100)
Antibody disorders 31/92 (33.7) 31/85 (36) 0/7 (0)
HGG 10/92 (11) 10/85 (12) 0/7 (0)
XLA 12/92 (13) 12/85 (14) 0/7 (0)
AGG 5/92 (5) 5/85 (6) 0/7 (0)
Other disorders 13/92 (14) 13/85 (15) 0/7 (0)
MHC II 6/92 (7) 6/85 (7) 0/7 (0)
HLA-DR 4/92 (4) 4/85 (5) 0/7 (0)

Serotyped
1 15/101 (15) 12/94 (13) 3/7 (43)
2 68/101 (67) 64/94 (68) 4/7 (57)
3 13/101 (13) 13/94 (14) 0/7 (0)
1 + 2 2/101 (2) 2/94 (2) 0/7 (0)
2 + 3 3/101 (3) 3/94 (3) 0/7 (0)
All type 2 associated 73/101 (72) 69/94 (73) 4/7 (57)

Outcome status
Dead 48/101 (48) 45/94 (48) 3/7 (43)
Stopped excreting 36/101 (36) 34/94 (36) 2/7 (29)
Alive (and excreting at last specimen) 8/101 (8) 7/94 (7) 1/7 (14)e
Unknown 9/101 (9) 8/94 (9) 1/7 (14)

AGG, agammaglobulinemia; CVID, common variable immunodeficiency disorder; HGG, hypogammaglobulinemia; HLA-DR, human leukocyte antigen-antigen D related; MHC II; major histocompatibility complex type II; SCID, severe combined immunodeficiency disorder; WHO, World Health Organization; XLA, X-linked agammaglobulinemia.

aDefined as excreting virus for ≥6 months and ≤5 years.

bDefined as excreting for >5 years.

cBased on 2016 World Bank Classification.

dSerotype of virus in most recent specimen available.

eThis case has been published (27).